Samuel Wagner

1.9k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Samuel Wagner is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Samuel Wagner has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Economics and Econometrics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel Wagner's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Economic and Financial Impacts of Cancer (3 papers). Samuel Wagner is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Economic and Financial Impacts of Cancer (3 papers). Samuel Wagner collaborates with scholars based in United States, United Kingdom and Germany. Samuel Wagner's co-authors include M. Colombo, Minshan Chen, Lewis R. Roberts, Joong‐Won Park, Myron Schwartz, Pei‐Jer Chen, Philip J. Johnson, Lucinda Orsini, Morris Sherman and Masatoshi Kudo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Samuel Wagner

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

2015 879 citations Joong‐Won Park, Minshan Chen et al. Liver International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Wagner United States	13	722	386	372	302	201	25	1.4k
Pierre Chan Hong Kong	23	555 0.8×	275 0.7×	359 1.0×	223 0.7×	278 1.4×	33	1.4k
Yvonne H. Sada United States	16	691 1.0×	839 2.2×	381 1.0×	278 0.9×	109 0.5×	54	1.5k
Virginia Clark United States	20	643 0.9×	742 1.9×	264 0.7×	142 0.5×	103 0.5×	57	1.4k
Alessio Cortellini Italy	22	226 0.3×	222 0.6×	1.1k 2.8×	426 1.4×	113 0.6×	130	1.7k
Daniel W. Nelson United States	18	223 0.3×	457 1.2×	338 0.9×	186 0.6×	65 0.3×	78	1.6k
Wen‐Tsung Huang Taiwan	15	461 0.6×	199 0.5×	368 1.0×	232 0.8×	346 1.7×	53	1.1k
Fadi Haddad United States	20	159 0.2×	160 0.4×	562 1.5×	262 0.9×	113 0.6×	190	1.7k
Catherine Frenette United States	25	1.2k 1.7×	917 2.4×	280 0.8×	132 0.4×	166 0.8×	87	1.8k
Kun‐Ming Rau Taiwan	20	261 0.4×	241 0.6×	459 1.2×	350 1.2×	162 0.8×	65	1.3k
Rudolf Morant Switzerland	17	287 0.4×	142 0.4×	1.1k 3.0×	465 1.5×	127 0.6×	36	1.8k

Countries citing papers authored by Samuel Wagner

Since Specialization

Citations

This map shows the geographic impact of Samuel Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Wagner more than expected).

Fields of papers citing papers by Samuel Wagner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Wagner. The network helps show where Samuel Wagner may publish in the future.

Co-authorship network of co-authors of Samuel Wagner

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Wagner. A scholar is included among the top collaborators of Samuel Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Wagner. Samuel Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Torres, Aracelis Z., Nathan C. Nussbaum, Christina M. Parrinello, et al.. (2022). Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Advances in Therapy. 39(6). 2831–2849. 13 indexed citations

Quinn, Casey, Louis P. Garrison, Michael B. Atkins, et al.. (2020). Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. Journal for ImmunoTherapy of Cancer. 8(2). e000648–e000648. 34 indexed citations

Gordon, Jason, et al.. (2018). Defining and Estimating the Cure Fraction Bias in Survival Modelling of Novel Immuno-Oncology Therapy Agents in Small-Cell Lung Cancer. Value in Health. 21. S211–S211. 1 indexed citations

Kotapati, Srividya, et al.. (2017). An expanded portfolio of survival metrics for assessing anticancer agents.. PubMed. 23(1). 54–61. 3 indexed citations

Othus, Megan, Aasthaa Bansal, Lisel Koepl, Samuel Wagner, & Scott D. Ramsey. (2016). Accounting for Cured Patients in Cost-Effectiveness Analysis. Value in Health. 20(4). 705–709. 60 indexed citations

Johnson, Peter, Wolfgang Greiner, Imad Al‐Dakkak, & Samuel Wagner. (2015). Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International. 2015. 1–9. 15 indexed citations

Park, Joong‐Won, Minshan Chen, M. Colombo, et al.. (2015). Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International. 35(9). 2155–2166. 879 indexed citations breakdown →

Hirji, Ishan, Emuella Flood, Diana Chirovsky, et al.. (2014). Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study. Journal of health economics and outcomes research. 2(1). 75–86. 1 indexed citations

Revicki, Dennis A., Alfons JM van den Eertwegh, Paul Lorigan, et al.. (2012). Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes. 10(1). 66–66. 46 indexed citations

10.

Cortes, Jörge E., Michael J. Mauro, Stuart L. Goldberg, et al.. (2011). Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY). Blood. 118(21). 4435–4435. 5 indexed citations

11.

Hu, Xiaohan, Wendy L. Golden, S. Bolge, et al.. (2010). Predictability of Future Attacks by Migraineurs: A Prospective Observational Study. Headache The Journal of Head and Face Pain. 50(8). 1296–1305. 11 indexed citations

12.

Hoda, M. Raschid, et al.. (2010). 547 Obesity as a risk factor for prostate cancer: a role for adipocytokines and involvement of tyrosine kinase pathway. European Journal of Cancer Supplements. 8(5). 139–140. 1 indexed citations

13.

Williams, Setareh A., Samuel Wagner, Hema Kannan, & S. Bolge. (2009). The Association Between Asthma Control and Health Care Utilization, Work Productivity Loss and Health-Related Quality of Life. Journal of Occupational and Environmental Medicine. 51(7). 780–785. 88 indexed citations

14.

Hauber, Brett, Ateesha F. Mohamed, F. Reed Johnson, et al.. (2009). Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta₂-agonist maintenance medications. Allergy and Asthma Proceedings. 30(2). 139–147. 22 indexed citations

15.

Xu, Yaping, et al.. (2009). T1033 Health-Related Quality of Life Associated with Chronic Constipation or Irritable Bowel Syndrome with Constipation. Gastroenterology. 136(5). A–485. 1 indexed citations

16.

Richardson, Lisa C., Wei Wang, Abraham G. Hartzema, & Samuel Wagner. (2007). The Role of Health-Related Quality of Life in Early Discontinuation of Chemotherapy for Breast Cancer. The Breast Journal. 13(6). 581–587. 52 indexed citations

17.

Lobo, Francis, Samuel Wagner, Cynthia R. Gross, & Jon C. Schommer. (2006). Addressing the issue of channeling bias in observational studies with propensity scores analysis. Research in Social and Administrative Pharmacy. 2(1). 143–151. 59 indexed citations

18.

Ye, Xin, et al.. (2005). Gaps in colorectal cancer outcomes research. Community Oncology. 2(1). 30–35. 1 indexed citations

19.

Caselitz, M, P. Flemming, Christiane Stern, et al.. (2004). Prognose des hepatozellulären Karzinoms nach neuen Stadieneinteilungen. DMW - Deutsche Medizinische Wochenschrift. 129(33). 1725–1730. 11 indexed citations

20.

Caselitz, M, M Gebel, Samuel Wagner, et al.. (1999). [Treatment of multilocular hepatocellular carcinoma (HCC) of 4.5 cm and 3.5 cm diameter using percutaneous ethanol injection in a patient with advanced liver cirrhosis].. PubMed. 37(12). 1175–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact